Alltrna has developed a tRNA platform that utilizes machine learning to design and optimize tRNA molecules for therapeutic applications, specifically targeting diseases caused by genetic mutations that result in premature stop codons. By restoring full-length protein production, Alltrna's approach has the potential to treat thousands of diseases stemming from similar genetic defects.
Funding
$122.1M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many diseases, both rare and common, arise from nonsense mutations that introduce premature stop codons in mRNA, leading to truncated protein production and disease. Current therapeutic approaches often target individual proteins or genes, lacking a unifying strategy for addressing the underlying cause of these diverse diseases.
Solution
Alltrna is developing tRNA-based therapeutics that address diseases caused by premature stop codons. The company's platform leverages machine learning to design and optimize tRNA molecules that can specifically recognize and read through these stop codons, enabling the production of full-length, functional proteins. This approach offers the potential to treat thousands of diseases sharing the same underlying genetic mutation, regardless of the affected gene or protein. By restoring protein production at the source, Alltrna aims to provide a single therapeutic modality for a wide range of genetically-driven conditions. The platform integrates tRNA sequence, structure, and modification data to design optimized tRNA molecules with desired therapeutic properties.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions focused on developing treatments for rare and common genetic diseases caused by premature stop codons.
Features
- Machine learning-driven tRNA design platform that integrates sequence, structure, and modification data
- tRNA molecules engineered to specifically read through premature stop codons
- High-throughput in vitro assays for testing and validating tRNA molecule function
- Automated data integration and analysis for improved tRNA molecule design
- Potential to address thousands of diseases caused by nonsense mutations